Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trial

Pfizer listed two new studies and updated two others this period.

• Elranatamab, a bispecific antibody targeting BCMA and CD3, is the subject of a new Phase 4, single-arm, not yet recruiting study in India for relapsed or refractory multiple myeloma. The study is being conducted in India following approval of elranatamab by the Central Drugs Standard Control Organization and is intended to fulfill a post-approval requirement, further characterizing the drug's safety and efficacy in Indian patients.¹ The structured enrollment figure is listed as 75 participants (estimated)¹, though approximately 100 participants are planned to be enrolled across approximately 10 study sites in India¹ per the study summary.
• Berobenatide, also known as PF-08653944 or MET097, is the subject of a new Phase 3, randomized, placebo-controlled, not yet recruiting trial called "VESPER-OSA 2," assessing the efficacy and safety of once-monthly berobenatide in adults with obstructive sleep apnea and overweight or obesity not receiving positive airway pressure therapy.² The trial plans to enroll 258 participants (estimated)², with the primary outcome being change from baseline in Apnea-Hypopnea Index at week 52, the number of apnea and hypopnea events per hour of sleep, assessed by polysomnography.²
• Tilrekimig, co-mixed with recombinant human hyaluronidase PH20 (rHuPH20), is the subject of a Phase 1, open-label, single-dose study listed as active, not recruiting. The study aims to learn how the body handles tilrekimig when given with rHuPH20, a medicine approved to help some medicines be taken up by the body when given together as a subcutaneous injection.³ The trial enrolled 12 participants (actual)³ at a single U.S. site.
• Etrasimod, tested in healthy lactating women, is listed as completed. The study aimed to figure out how much etrasimod ends up in breast milk after taking it for several days, working with at least 8 healthy breastfeeding women who took a 2 mg dose daily for 7 days while staying at the testing site.⁴ Final enrollment was 8 participants (actual)⁴, with primary completion recorded on 2026-09-18.